FR2566403B1 - Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques - Google Patents

Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques

Info

Publication number
FR2566403B1
FR2566403B1 FR8409704A FR8409704A FR2566403B1 FR 2566403 B1 FR2566403 B1 FR 2566403B1 FR 8409704 A FR8409704 A FR 8409704A FR 8409704 A FR8409704 A FR 8409704A FR 2566403 B1 FR2566403 B1 FR 2566403B1
Authority
FR
France
Prior art keywords
imidazolides
intermediates
synthesis
obtaining
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8409704A
Other languages
English (en)
Other versions
FR2566403A1 (fr
Inventor
Franz K Jansen
Pierre Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR8409704A priority Critical patent/FR2566403B1/fr
Priority to US06/743,659 priority patent/US4670563A/en
Priority to CA000483680A priority patent/CA1283661C/fr
Priority to DE8585401200T priority patent/DE3569732D1/de
Priority to AT85401200T priority patent/ATE42545T1/de
Priority to EP85401200A priority patent/EP0169112B1/fr
Priority to JP60135216A priority patent/JPH0625143B2/ja
Publication of FR2566403A1 publication Critical patent/FR2566403A1/fr
Application granted granted Critical
Publication of FR2566403B1 publication Critical patent/FR2566403B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8409704A 1984-06-20 1984-06-20 Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques Expired FR2566403B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR8409704A FR2566403B1 (fr) 1984-06-20 1984-06-20 Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques
US06/743,659 US4670563A (en) 1984-06-20 1985-06-11 Imidazolides as intermediates for the synthesis of cytotoxic conjugates
CA000483680A CA1283661C (fr) 1984-06-20 1985-06-11 Imidazolides, leur preparation, et leur emploi a titre d'intermediaires pour la synthese de conjugues cytotoxiques
DE8585401200T DE3569732D1 (en) 1984-06-20 1985-06-18 Imidazolides, process for obtaining them and their use as intermediates in the synthesis of cytotoxic conjugates
AT85401200T ATE42545T1 (de) 1984-06-20 1985-06-18 Imidazolide, verfahren zu deren herstellung und deren anwendung als zwischenprodukte in der synthese von cytotoxischen nebenprodukten.
EP85401200A EP0169112B1 (fr) 1984-06-20 1985-06-18 Imidazolides, procédé d'obtention et application à titre d'intermédiaires de synthèse de conjugués cytotoxiques
JP60135216A JPH0625143B2 (ja) 1984-06-20 1985-06-20 イミダゾリド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8409704A FR2566403B1 (fr) 1984-06-20 1984-06-20 Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques

Publications (2)

Publication Number Publication Date
FR2566403A1 FR2566403A1 (fr) 1985-12-27
FR2566403B1 true FR2566403B1 (fr) 1986-11-07

Family

ID=9305247

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8409704A Expired FR2566403B1 (fr) 1984-06-20 1984-06-20 Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques

Country Status (1)

Country Link
FR (1) FR2566403B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248040B1 (fr) * 1985-11-29 1993-03-24 Consolidated Pharmaceuticals Limited Composes conjugues a des anticorps de ricine

Also Published As

Publication number Publication date
FR2566403A1 (fr) 1985-12-27

Similar Documents

Publication Publication Date Title
FR2552760B1 (fr) Procede pour l'obtention de derives de carbostyrile et intermediaires de synthese
FR2645533B1 (fr) Procede de synthese de sulfonylimidures
FR2583772B1 (fr) Nouveaux supports, la preparation de ces supports, les intermediaires nouveaux obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
RO93871A (fr) Procede d'obtention des derives de propargyloxyacetonitryle substitus
MC210A7 (fr) Composes beta-lactame,la methode de sa preparation et la composition pharmacologique pour la therapie des maladies infectieuses et les moyens de sa synthese
FR2595352B1 (fr) Derives de l'indole utiles comme medicaments et procede et intermediaires pour leur preparation
FR2662178B1 (fr) Procede de preparation d'intermediaires utiles dans la synthese de benzothiazepines.
MC1691A1 (fr) Procede de synthese de derives de 4-amino-2-phenylquinolines et intermediaires de synthese
FR2566403B1 (fr) Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques
FR2574429B1 (fr) Acylglycannes extraits de klebsiella, leur procede d'obtention, leur application a titre de medicaments et les compositions les renfermant
FR2570069B1 (fr) Procede de synthese d'un aluminosilicate cristallin
FR2558471B1 (fr) Procede de preparation d'aspartyl peptides, et nouveaux intermediaires de synthese
FR2608157B1 (fr) Nouveaux derives de l'azaspirodecane, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant et intermediaires
FR2620130B1 (fr) Nouveaux polysaccharides hydrosolubles, leur procede d'obtention, leur application a titre de medicaments et preparation les renfermant
FR2593506B1 (fr) Procede de synthese de diorganomonothiophosphinates
HUT37356A (en) Process for producing oral pharmaceutical compositions of retaed activity
FR2641784B1 (fr) Procede de preparation de derives du chromanne et intermediaires de synthese
PT81816A (fr) Process de synthese d'un alcool tertiaire
FR2589479B1 (fr) Nouvel enzyme, son procede d'obtention et son application a la preparation de n-(l-aspartyl-1)l-phenylalaninate de methyle
FR2650506B1 (fr) Galactanne extrait de klebsiella, procede d'obtention et application a titre de medicament
PT83055A (fr) Procede de synthese pour la preparation d'un nouveau benzodioxepanne
FR2573430B1 (fr) Nouveaux derives de benzopyranones, leur procede d'obtention et les composes pharmaceutiques en renfermant
FR2611712B1 (fr) Nouveaux derives n-substitues de l'alpha-mercaptomethyl benzene propanamide, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant
FR2572072B1 (fr) Procede de preparation de derives d'indole
FR2585723B1 (fr) Procede ameliore d'obtention de polysaccharides par fermentation

Legal Events

Date Code Title Description
ST Notification of lapse